MedTrace Logo

Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment

NCT07102030 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2025-08-03

No results posted yet for this study

Summary

The goal of this observational study is to investigate different phenotypes among patients with SLE and to compare with matched general population controls. The main questions we aim to answer are:

A To investigate if subgroups of patients with systemic lupus erythematosus (SLE) defined by autoantibodies, genetic predisposition or biomarkers, rather than the present diagnostic entities account for the high risk of premature vascular disease.

B To perform in depth studies of selected patient groups to shed light on the autoimmune mechanisms behind antiphospholipid (aPL) antibodies and nephritis and their association to vascular disease in SLE and APS Participants will be investigated in person by a nurse and a rheumatologist. Data on previous and present disease characteristics, anthropometric measurements and health related quality of life (according to selfreported questionnaires) will be entered into a data base. Blood samples (plasma serum and DNA), urine and saliva is stored in a corresponding biobank.

Researchers will compare identified subgroups of SLE patients to each other and to matched population controls.

Conditions

Sponsors & Collaborators

  • Karolinska Institutet

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Reumatikerförbundet

    collaborator UNKNOWN

  • Region Stockholm

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-15
Primary Completion
2029-12-31
Completion
2032-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07102030 on ClinicalTrials.gov